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Serotonin-mediated mechanisms, in particular via the serotonin transporter (SERT), are thought
to have an effect on food intake and play an important role in the pathophysiology of obesity.
However, imaging studies that examined the correlation between body mass index (BMI) and
SERTare sparse and provided contradictory results. The aim of this study was to further test the
association between SERT and BMI in a large cohort of healthy subjects. Methods: 127 subjects
of the ENC DAT database (58 females, age 52718 years, range 20–83, BMI 25.273.8 kg/m2,
range 18.2–41.1) were analysed using region-of-interest (ROI) and voxel-based approaches to
calculate [123I]FP-CIT specific-to-nonspecific binding ratios (SBR) in the hypothalamus/thalamus
and midbrain/brainstem as SERT-specific target regions. Results: In the voxel-based analysis,
SERT availability and BMI were positively associated in the thalamus, but not in the midbrain.
In the ROI-analysis, the interaction between gender and BMI showed a trend with higher
correlation coefficient for men in the midbrain albeit not significant (0.033 SBR m2/kg, p=0.1).
Conclusions: The data are in agreement with previous PET findings of an altered central
serotonergic tone depending on BMI, as a probable pathophysiologic mechanism in obesity, and
should encourage further clinical studies in obesity targeting the serotonergic system.
& 2014 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Obesity rates have reached epidemic proportions world-
wide, and might become the number one preventable public
health threat for the 21st century (Sturm, 2002) with
high socio-economic impact due to serious medical sequ-
elae, e.g. an increase in type II diabetes mellitus. Despite
rapid progress in identifying the social, environmental and
genetic causes of overeating, the mechanisms by which
these factors result in obesity are not resolved. Regarding
the central mechanism thought to be relevant for obesity,
the monoaminergic systems seem to play a pivotal role in
reward processing (i.e. the dopaminergic pathways of the
ventral tegmental area, nucleus accumbens, and frontal
cortex) (Volkow et al., 2011), stress-mediation (in particular
norepinephrine; Hainer et al., 2006), and the homoeostatic
control of feeding. With respect to this, the modulation by
serotonin of eating behaviour integrates homoeostatic and
hedonic aspects as well as reward regulation at the inter-
section of the mesolimbic system, hypothalamus and brain-
stem (Hoebel, 1985). Changes in serotonergic functioning,
as a main factor in the regulation of eating behaviour and
energy balance, were shown in a variety of animal and
clinical studies. Recently, a study in genetically engineered
mice showed that knocking out the serotonin transporter
(SERT) leads not only to hypophagia and hyperleptinemia
but also to insulin resistance, hepatic steatosis, and obesity
independent of food intake (Chen et al., 2012). Other
studies on SERT knock-out mice also showed increased
levels of abdominal fat and susceptibility to obesitynt of Nuclear Medicine, Universit
7 18069.
in.uni-leipzig.de (S. Hesse).(Homberg et al., 2010; Uçeyler et al., 2010). In addition,
selectively bred polygenic obese rats had lower SERT
binding when compared to polygenic diet-resistant rats
(Ratner et al., 2012), whereas no change in SERT was seen
in diet-induced obesity in outbred rats. This was not the
case in a mouse model: diet resistant mice have lower SERT
binding than diet-induced obese mice (Huang et al., 2004).
Also, a recent imaging study showed that obesity is asso-
ciated with high serotonin-4 receptor availability in the
brain reward system (Haahr et al., 2012). Evidence for a
serotonergic involvement in the pathophysiology of satiety
and overeating also came from the efficacy of anorectic
drugs. For example, sibutramine (Reductil) targeting the
SERT as well as the norepinephrine transporter (NET) has an
appetite-suppressing, anorexogenic effect (Hainer et al.,
2006). Hence, both monoaminergic systems, and in parti-
cular the presynaptically located transporters, are likely to
represent key biochemical substrates in the intrinsic control
of eating, and their failure in function, or compensatory
change in expression, are thought to underlie overeating.
Only few studies have been performed that applied
single-photon emission computed tomography (SPECT) or
positron emission tomography (PET) with radiotracers for
the SERT to unravel altered SERT availability in vivo in
obesity or that looked into the association between BMI and
SERT. Talbot et al. (2010) reported on a PET study with the
highly SERT-selective radiotracer [11C]DASB, which was
initiated to investigate mechanisms underlying the clinical
efficacy of sibutramine. They found SERT occupancy, by
clinical doses of sibutramine, of modest magnitudey of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany.
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necessary for sibutramine's antiobesity effect in humans,
and suggested that the hypophagic effect requires instead
the co-inhibition of both SERT and NET. Given that the
serotonergic system is a tonic, modulatory network of fibres
stemming from the midbrain raphe nuclei, one might
speculate that changes in either the brainstem SERT or the
SERT at nerve terminals (e.g., in the diencephalon) are
altered when external stimuli disturb the homoeostasis to
maintain the serotonergic tone. Obesity and the body mass
index (BMI) as a marker for overweight might therefore be
associated with a change in regional SERT availability in
human. First in vivo [11C]DASB PET studies on SERT revealed
contradictory findings, either a positive or an inverse
correlation between SERT availability and BMI (Hesse
et al., 2009b; Erritzoe et al., 2010), respectively. These
studies in healthy volunteers were hampered by a lack of a
larger sample of subjects with higher BMI (435 kg/m2) so
that the curves may have been driven by some outliers in
the upper range. A role for the SERT in obesity and BMI is
thus plausible, but not yet conclusively demonstrated.
The objective of this study is to analyse extrastriatal SERT
binding in an unique European database of [123I]FP-CIT SPECT
scans of healthy volunteers to test for an association between
SERTavailability and BMI with a large BMI range. Recent studies
showed that [123I]FP-CIT does not only bind to the dopamine
transporter (DAT) in vivo, but also to extrastriatal SERTs (Booij
et al., 2007). Based on the mentioned preliminary SERT PET
studies in conjunction with BMI, we hypothesised that BMI and
SERT binding ratios are correlated in healthy volunteers.
2. Experimental procedures
This project was part of the collaborative European Association of
Nuclear Medicine (EANM) Research Ltd. (EARL) initiative “European
Database of [123I]FP-CIT SPECT scans of healthy controls (ENC-
DAT)”, which started in 2007 and was successfully completed in
2010 (13 European institutions in 10 European countries recruiting
151 subjects) (Dickson et al., 2012; Varrone et al., 2013).2.1. Subjects
The subjects were healthy volunteers fulfilling the inclusion and
exclusion criteria as previously published (Varrone et al., 2013; van
de Giessen et al., 2013). In brief, attendees had an age between 20 and
90 years, no evidence or history of neurological and psychiatric
disorders as excluded by a neurologist, motor complaints as assessed
with the Unified Parkinson's Disease Rating Scale (UPDRS), a Symptom
Checklist-90-R (SCL-90-R) score o63 to ensure only minimal psycholo-
gical problems, a Beck Depression Inventory (BDI) score under 9 points,
and no evidence for cognitive impairment, as assessed with the Mini-
mental state examination (MMSE). Subjects on medication known to
affect DAT or SERT binding were not included in the study. Urine based
screening tests for drug abuse was obtained in all subjects to exclude
the use of illegal substances. They all had an MRI scan without signi-
ficant diffuse or confluent white matter hyperintensities in T2-weighted
images for exclusion of significant structural pathologies and for anato-
mical co-registration with SPECT data (see below).
All subjects underwent a general physical examination, including
weight and height measurement for BMI calculation. The protocol
was in accordance with the declaration of Helsinki and approved by
the Medical Ethical Committees of all participating centres and all
subjects provided written informed consent.2.2. SPECT acquisition and data processing
Each subject underwent one SPECTscan starting 3–4 h after intravenous
application of 185 MBq [123I]FP-CIT (DaTSCAN; GE Healthcare), prior
to which they received thyroid blockade (see Varrone et al. (2013) for
more details of the scanning protocols). SERT specificity of diencepha-
lon–midbrain [123I]FP-CIT binding was shown in vivo in human by
displacement studies using the selective serotonin reuptake inhibitor
paroxetine (Booij et al., 2007; Ziebell et al., 2010). Technical data and
standardized data for the SPECT cameras that were used in the trial
acquisition were described elsewhere (Dickson et al., 2012; Tossici-Bolt
et al., 2011). All scans were reconstructed by the core lab on HERMES
(HERMES Medical Solution, Stockholm, Sweden) and corrected for
attenuation and scatter in the core centre.2.3. Region-of-interest (ROI) analysis
For ROI analysis, the SPECT data were transferred to a HERMES
workstation and manually co-registered with the MRI scans by using
the HERMES MultiModality software following a previously described
procedure (Hesse et al., 2003, 2009a). Briefly, the individual MRI scan
was reoriented towards the anterior–posterior commissure lines based
on a normal standardized MRI. Then, the individual SPECT data were co-
registered onto the realigned individual MRI in all three (x, y, and z)
planes and the ROIs, which are atlas-based predefined in the normal
standardized MRI, were adjusted to the individual anatomy. The uptake
in each ROI with the highest mean count density in adjacent slices
comprising the entire brain structure, i.e. the SERT-rich regions
thalamus/hypothalamus (diencephalon) and midbrain/brainstem was
determined (one continuous ROI from the thalamus level to the
upper brainstem providing two peaks of mean count density, one
at the thalamus/hypothalamus and one at the upper brainstem level,
Figure 1). The occipital cortex was used as the reference region repre-
senting non-specific binding to calculate the specific-to-nonspecific
binding ratio (SBR), which is the (activity in target-ROI divided by the
activity in occipital cortex) minus 1.
Statistical analysis on the interaction between ROI (SBR) and BMI
data considering age, gender, and scan start (after injection) was
performed using either PASW/SPSS 20 (IBM, Armonck, NY) or the
software R (http://www.r-project.org/, R Development Core Team,
2011), version 2.14.0, and is based on a linear model including
camera-type as a factor, scan start, gender (Ruhé et al., 2009), age
(Hesse et al., 2003), BMI (as continuous variables) and the higher
terms gender age and gender Note please retain the same space
before multiplication symbol as given in the previous lineBMI. Terms
are then dropped in a stepwise fashion based on Akaike's information
criterion and the final model is assessed using a marginal t-statistic.
p-Values ofo0.05 were considered to be statistically significant.2.4. Voxel-based analysis
Voxel-based analysis was additionally applied using SPM8 running on
MATLAB 7.5 for Windows (MathWorks, Natick, MA) (Figure 2). The
procedure has been described in detail elsewhere (van de Giessen
et al., 2013). To obtain individual parametric maps of SERT SBR, the
uptake in the occipital cortex was extracted for each scan and SBR
calculated for the full brain by (activity per voxel divided by the activity
in occipital cortex) minus 1. The ROI for the occipital cortex was drawn
manually on the mean scan in ITK-SNAP (version 2.1, PICSL, University
of Pennsylvania). A regression analysis was performed in SPM8 with
the SBR maps as dependent variable, BMI as independent variable and
age, gender, scan time (3 or 4 h post-injection), and camera-type
as covariates. Accordingly, comparison of images between groups
(BMIr25 kg/m2 versus BMI425 kg/m2 and BMIr25 kg/m2 versus
BMIZ30 kg/m2) was done with ANCOVA with SBR maps as dependent
variable, BMI group as independent variable and age, gender, scan time,
Figure 1 Co-registration of the SPECT to the individual MRI data for region-of-interest (ROI) analysis with HERMES MultiModality
using mutual information algorithm and manually adapted realignment in three-dimensions (A). The dotted lines display the levels of
axial slices. Bottom row illustrates co-registered data side-by-side with the target ROI (1) at the level of the hypothalamus (B) and at
the midbrain level (C) indicating two peaks of mean count density within the one continuous placed region.
1243SERT and BMI in healthy Europeansand camera-type as covariates. All analyses were confined to either
diencephalon or brainstem using explicit masking with the target ROI
drawn on the mean scan using intensity thresholding in ITK-SNAP
(Figure 2). p-Valueso0.05, family-wise error corrected (FWE corr),
were considered significant.3. Results
The final sample eligible for this ENC DAT sub-study (good
image quality, full scatter windows, no truncation of data,
i.e. scanning of the entire midbrain or occipital cortex)
consisted of 127 subjects (58 female) with a mean age of
52.3718.3 years (range 20–83) and mean BMI of 25.27
3.8 kg/m2 (range 18.2–41.1). We did not include one male
subject for the entire analysis, because midbrain ROI partly
fell outside the scanned part of the brain (as it was regis-
tered on the mean brain), which would have affected the
voxel-based analysis. In the stratified groups, age differed
between individuals with BMIr25 kg/m2 (n=66; 47.57
19.7 years) and BMI425 kg/m2 (n=61; 57.4715.3 years;
p=0.001) or BMIZ30 kg/m2 (n=12; 56.7715.7 years;
p=0.046). SBR in the diencephalon and midbrain did not
differ between the groups that were assessed 3–4 h post-
injection (p=0.63 for the thalamus, and p=0.98 for the
midbrain, data not shown in detail).3.1. ROI analysis
The analysis of the diencephalon SBR data shows that the
effect of different cameras is large, which resulted in a
correction for Infinia camera (GE Healthcare, Fairfield, CT)
of 0.5 (p=0.0006, 95% CI [0.2, 0.8]) and for the Varicamcamera (GE Healthcare, Fairfield, CT) of 0.4 (p=0.009,
95% CI [0.8, 0.1]) as part of the linear model.
Age was found to be negatively associated with a
coefficient of 0.006 SBR/year (p=0.02, 95% CI [0.010,
0.001]). The age dependence was almost entirely driven
by two data points, however, and the p-value changed to
0.08 and 0.1 after removing these two points (see Figure 3).
BMI and SBR of the diencephalon showed no significant
association (p=0.1 for the full model), especially after
removing the two aforementioned outliers (p=0.8).
The SBR for the midbrain also showed strong effects for
the same two cameras with the correction of 0.37 for Infinia
(p=0.009, 95% CI [0.1, 0.6]) and 0.33 for Varicam
(p=0.03, 95% CI [0.6, 0.03]). There was a weak and
non-significant association with age with a coefficient of
0.004 SBR/year (p=0.1), whereas BMI showed little
evidence for an association (p=0.6) although the interac-
tion in the full model between gender and BMI showed a
slight trend, whereby men's SBR values increase more
quickly with BMI for men than for women (coefficient for
men is: 0.033 SBR m2/kg, p=0.1 and zero for women by
construction), see Figure 4 for an illustration using linear
regression.
3.2. Voxel-based analysis
There was no significant correlation with BMI and midbrain
SERT, or with age and gender. But in the thalamus, a positive
correlation between BMI and thalamus SERT in a cluster of
6 voxels (FWE corr, maximum t-value in cluster (max t)
=3.79, p=0.020) (Figure 5), and a negative correlation
between age and thalamus SERT in a cluster of 42 voxels
(FWE corr, max t=5.38, p=0.002) were found. Comparing
Figure 3 Negative correlation between SERT availability and
age in the thalamus/hypothalamus. The line represents the fit
for all values in female and the dotted line the fit for all male
values. Note the spread of values reducing R2 (0.06 in female,
0.02 in male subjects) and the two outliers as mentioned in
the text.
Figure 4 Correlation between SERT availability and BMI in the
midbrain. The line represents the fit for all values in female and
the dotted line the fit for all male values. Note the spread of
values reducing R2 (0.02 in female, 0.08 in male subjects).
Figure 2 Mean scan with thalamus mask (A) and the midbrain
mask (B) for voxel-based SPM analysis.
S. Hesse et al.1244subjects with BMIr25 kg/m2 and subjects with BMI425 kg/m2
there was no group difference in midbrain binding. Comparable
results were found for the group comparison between subjects
with BMIr25 kg/m2 and subjects with BMIZ30 kg/m2, again
there was no group difference. In the thalamus, binding is
higher in the BMI425 kg/m2 group than in BMIr25 group
(cluster size: 11 voxels, FWE-corr, max t=4.07, p=0.009), and
age and thalamus binding did show a negative correlation (38
voxels, FWE-corr, max t=5.23, p=0.001). For BMIZ30 kg/m2
versus BMIr25 kg/m2, the SERT binding is higher in the
Z30 kg/m2 group in the thalamus (3 voxels, FWE-corr, max
t=3.76, p=0.025) and again a negative correlation between
age and binding (29 voxels, FWE-corr, max t=4.69, p=0.002)
was revealed.
4. Discussion
In vivo human data of SERT availability in obesity or its
correlation with BMI are still sparse and rather contra-
dictory. Since SERT represent a major target of anorectic
pharmacotherapy as mentioned above, studies were encour-
aged to clarify whether there is an association between
SERT availability and BMI as a marker of obesity. The main
finding of this study was that a firm result regarding the
association between SERT availability and BMI was notobtained by the study data. However, the results of
both voxel-based and ROI-analysis gave some clues for
future research on the relationship between BMI and the
brain serotonin system. In particular, voxel-based analysis
indicates a positive correlation between SERTand BMI in the
thalamus. In the ROI analysis the interaction between
gender and BMI showed a trend with a higher coefficient
Figure 5 SPM analysis demonstrating the correlation between thalamic uptake indicating SERT availability and body-mass-
index (BMI).
1245SERT and BMI in healthy Europeansfor men but this was of weaker significance compared with
the voxel-based results.
These results are in agreement with previous findings of a
positive correlation between BMI and SERT availability in a
[123I]nor-β-CIT SPECT study in monozygotic twin pairs with
acquired obesity (Koskela et al., 2008). It is interesting that
this study also reported a significant effect in the thalamus
but not in the midbrain. Like [123I]FP-CIT, [123I]nor-β-CIT
binds in the striatum predominantly to the DATs, but in
extrastriatal areas to the SERT, so, these radiotracers have
comparable properties. Our present observations with this
non-selective SPECT radiotracer are also in line with our
own preliminary data of a positive correlation between SERT
availability and BMI, measured with the SERT-selective [11C]
DASB (Hesse et al., 2009b). Contrarily, the study by Erritzoe
et al. (2010) indicated a negative association between BMI,
also in subcortical brain areas. The main reason for this
discrepancy may be the low numbers of obese subjects in all
studies, which makes single data points highly influential. In
obesity, however, alterations of the presynaptic serotonergic
function, i.e. the SERT, and changes of serotonergic tone were
observed in recent animal studies, not only in the brain
(Ratner et al., 2012) but also in the gut (Bertrand et al.,
2012). For example, the study of Huang et al. (2004) showed
increased SERT in diet-induced obesity, but the results of small
laboratory animal studies are not consistent, even in the
direction of the changes in SERT expression (Homberg et al.,
2010; Uçeyler et al., 2010).
From a pathophysiological point of view, higher SERT
availability at higher BMI theoretically indicates a higher
SERT recruitment in healthy persons, most likely due to
changes in extracellular serotonin. This serotonin imbalance
either due to food overload or overactive reward and
homoeostatic circuits (stress-induced) may lead to higher
serotonin recruitment as well, and high SERT can also be a
compensatory upregulation in the case of high serotonin
levels (Ramamoorthy et al., 2011). Nevertheless, at this
moment we do not know whether higher SERT availability
can be a compensatory mechanism to chronic lower or
higher extracellular serotonin concentrations. Indeed, (sub)
acute lowering did not induce changes in SERT binding in
humans (Praschak-Rieder et al., 2005), but this does not
exclude that chronic changes in serotonin concentration
may influence SERT binding. For studying the role of
serotonin in obesity, it may be of interest to develop tools
to assess extracellular serotonin concentrations, but this
approach has not been successful yet (Pinborg et al., 2012).
Low serotonin levels are associated with hyperphagia andweight gain (Lam et al., 2010). So, it can also be hypothe-
sised that high SERT availability is a susceptibility for high
BMI, as high SERT concentration leads to low synaptic
serotonin levels and thus to hyperphagia. Since serotonin
is a tonic, modulatory network and the major mode of
transmission for serotonin in the brain is volume transmis-
sion with widespread serotonergic innervation from the
raphe nuclei, SERT availability is not necessarily simply
correlated with either downregulation or upregulation of
the presynatic serotonin concentration. One can rather
assume that input from internal and external sources
differentially activate serotonergic tone in obese versus
lean controls.
It is speculative to which part of the thalamus the
presently observed significant small area in the thalamus
belongs. This particular area, however, seems to involve the
more midline part of the thalamus (the paraventricular
thalamus, the pulvinar) rather than the hypothalamus. Inter-
estingly, this part of the thalamus is responsible for the
control response to chronic stress mediated by the seroto-
nergic system and consequently the expression of SERT may
play a role (reviewed by Price and Drevets (2010)). As the
study by Koskela et al. (2008) did apply ROI analysis and not
voxel-based analysis, it is unknown whether the reported
effect in the thalamus was located in the same thalamic
region in that study. Because we find this effect only in the
voxel-based analysis in clusters that are not very large, future
studies are necessary to replicate this finding.
For the interpretation of the present results, however,
some drawbacks and limitations have to be mentioned.
To overcome the fact that the delineation of the SERT target
areas in the diencephalon and midbrain (raphe) is difficult
because they are small, and also the specific-to-nonspecific
binding ratios in these areas are not that high, we used
different (independent) approaches to analyse the data
which are either voxel-based (without MRI co-registration)
or based on anatomically re-aligned SPECT scans. With both
methods the tendency to higher values at higher BMI was
shown in SERT-rich brain areas although the regions differed
depending on the method used. One reason for the dis-
crepancy might be that the ROIs were including the whole
target structure, while the voxel-based analysis provided
significant clusters only in a small volume of the thalamus.
So, FWE correction allows considering significant clusters of
3–6 voxels, which is at the border of the spatial resolution of
gamma cameras. Such explanation is more likely than that
different equilibrium conditions in the thalamus and mid-
brain might have influenced the study results. In a recent
S. Hesse et al.1246study in healthy controls, we showed that specific-to-
nonspecific [123I]FP-CIT binding ratios in the midbrain and
diencephalon were significantly higher 2 h compared to 1 h
after injection and remained stable between 2 and 3 h after
injection (Koopman et al., 2012). Consequently, 3 h after
injection is a reasonable time-point to assess extrastriatal
SERT binding with [123I]FP-CIT SPECT in vivo, although it has
not been formally tested if this ratio is also stable up to 4 h
p.i. As a fact, the binding behaviour of [123I]FP-CIT in the
diencephalon–brainstem is slightly different from that in the
striatum (see van de Giessen et al. (2013)) representing
mainly DAT Although radiotracers derived chemically from
cocaine like [123I]FP-CIT and [99mTc]TRODAT are frequently
used to assess striatal DAT binding e.g., in studies on obesity
(van de Giessen et al., 2013; Chen et al., 2008), SERT
findings obtained with non-selective radiotracers should be
confirmed by studies using selective SERT tracers to further
disentangle the obese phenotype and underlying monoami-
nergic mechanism.
Another limitation of this study is the age difference
between the BMI groups. We therefore added age as a
covariate to all analyses. Furthermore, BMI was positively
correlated with SERT availability in the thalamus. Because
age was negatively correlated with SERTavailability and BMI
and age are negatively associated with each other, it is
unlikely that the presently reported positive association
between BMI and thalamus SERT availability was actually
due to age differences between groups.
Gender differences are also believed to play a major role
in regulating body-weight, as suggested by recent imaging
data on brain structure as well as performance (Horstmann
et al., 2011) and they may affect SERT/brainstem mono-
amine transporter availability (Staley et al., 2001), but the
mechanisms (e.g. neuroendocrine effects) are not fully
understood yet. Nevertheless, gender was added as a cova-
riate to all analyses as well. In the ROI analysis, however,
the effect of gender was small.
Furthermore, the trend for a genderBMI interaction
effect on SERT binding in the thalamus in the ROI analysis
should be interpreted with caution, as the effect size was
small.
Genetic contribution to SERT binding in obesity is of
interest, since the SERT promoter polymorphism might be
related to obesity (Fuemmeler et al., 2008; Lan et al., 2009;
Sookoian et al., 2008). Further, hypermethylation of the
SERT promoter region is associated with obesity (Zhao
et al., 2013). For this study, no genetic data were available,
but it would be very interesting to incorporate this in future
studies. These studies shall also include psychological,
stress-related and social variables, which all might correlate
with SERT outcome measures and hence should be con-
trolled for in the analyses. Last but not least as is the case in
all the available in vivo SERT PET and [123I]FP-CIT imaging
studies, the ENC-DAT study was also hampered by the limited
number of heavily obese subjects, which as mentioned in every
case seem to be the crucial data in determining the fitting
curve.
In conclusion, the data are in agreement with previous
PET findings of an altered central serotonergic tone depend-
ing on BMI, as a probable pathophysiologic mechanism in
obesity, and should encourage further clinical studies in
obesity targeting the serotonergic system.Role of funding source
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